In Re Application Of: Kevin S. Weadock, et al. Serial No. 10/085,738 February 28, 2002 Unassigned 3731 Title: SPONGE FOR CREATING AN ANASTOMOSIS BETWEEN VESSELS Address to: Assistant Commissioner for Patents Washington, D.C. 20231 37 CFR 1.97(b) 1. 2 The Information Disclosure Statement submitted herewith is being filed within three months of the filling of a national application other than a continued prosecution application under 37 CFR 1.53(d), within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114. 37 CFR 1.97(c) 2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: the statement specified in 37 CFR 1.97(e); OR the fee set forth in 37 CFR 1.17(p).			
Title: SPONGE FOR CREATING AN ANASTOMOSIS BETWEEN VESSELS Address to: Assistant Commissioner for Patents Washington, D.C. 20231 37 CFR 1.97(b) 1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114. 37 CFR 1.97(c) 2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: the statement specified in 37 CFR 1.97(e); OR the fee set forth in 37 CFR 1.17(p).			
Title: SPONGE FOR CREATING AN ANASTOMOSIS BETWEEN VESSELS Address to: Assistant Commissioner for Patents Washington, D.C. 20231 37 CFR 1.97(b) 1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filling of a request for continued examination under 37 CFR 1.114. 37 CFR 1.97(c) 2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: the statement specified in 37 CFR 1.97(e); OR the fee set forth in 37 CFR 1.17(p).			
Assistant Commissioner for Patents Washington, D.C. 20231 37 CFR 1.97(b) 1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114. 37 CFR 1.97(c) 2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: the statement specified in 37 CFR 1.97(e); OR the fee set forth in 37 CFR 1.17(p).			
Assistant Commissioner for Patents Washington, D.C. 20231 37 CFR 1.97(b) 1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114. 37 CFR 1.97(c) 2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: OR the statement specified in 37 CFR 1.97(e); OR			
 1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114. 37 CFR 1.97(c) 2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: the statement specified in 37 CFR 1.97(e); OR the fee set forth in 37 CFR 1.17(p). 			
of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114. 37 CFR 1.97(c) 2. □ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: □ the statement specified in 37 CFR 1.97(e); OR □ the fee set forth in 37 CFR 1.17(p).			
 2. □ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: □ the statement specified in 37 CFR 1.97(e); OR □ the fee set forth in 37 CFR 1.17(p). 			
CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: the statement specified in 37 CFR 1.97(e); OR the fee set forth in 37 CFR 1.17(p).			
OR ☐ the fee set forth in 37 CFR 1.17(p).			
the fee set forth in 37 CFR 1.17(p).			
" ·			
· i			
APR 2 3 2003			
TECHNOLOGY CENTER R3700			

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))			Docket No. 15314 (HRT-1636)	
In Re Application: Kevin S. Weadock, et al. APR 2 1 2003				
Serial No.	Filing Date	Examiner	Group Art Unit	
10/085,738	February 28, 2002	Unassigned	3731	
SPONGE FOR CREATING AN ANASTOMOSIS BETWEEN VESSELS				
Payment of Fee (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))				
 ☑ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below. A duplicate copy of this sheet is enclosed.				
account is being facsimile transmitted to the United States Patent and Trademark Office (F (Date)		4/17/2003 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.		
Signature		Signature of Person Mailing)Correspondence Mishelle Mustafa		
Typed or Printed Name of Person Signing Certificate Typed or Printed Name of Person Mailing Certificate		on Mailing Certificate		
*This certificate ma deposit account. Thomas Spinelli Registration No.: 39,533 Scully, Scott, Murphy & P 400 Garden City Plaza Garden City, New York 1 (516) 742-4343		A	ECEIVED APR 2 3 2003 OLOGY CENTER R3700	
cc:				

. . .